Jul 22, 2021 8:00 am EDT Ocuphire Announces Publication in the Journal of Cellular Signaling Featuring its Oral Ref-1 Inhibitor APX3330 in Phase 2 Trial for the Treatment of Retinal Disease
Jul 9, 2021 5:00 pm EDT Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Jun 30, 2021 7:15 am EDT Ocuphire’s VEGA-1 Phase 2 Trial in Presbyopia Meets Primary and Secondary Endpoints
Jun 8, 2021 4:10 pm EDT Ocuphire Announces Closing of $15 Million Registered Direct Offering Priced At-the-Market
Jun 8, 2021 8:00 am EDT Ocuphire Announces Appointment of Jay S. Pepose, M.D., Ph.D. to Its Board of Directors
Jun 4, 2021 9:04 am EDT Ocuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
May 20, 2021 7:30 am EDT Ocuphire to Host Key Opinion Leader Event on Nyxol® as a Potential New Treatment Option for Reversing Pharmacologically Induced Mydriasis